A Focus on Metabolic Parameters and Weight Changes With an Atypical Antipsychotic for Bipolar I Disorder

03/10/2025

The use of atypical antipsychotics in the treatment of bipolar I disorder (BP-1) can be associated with changes in metabolic parameters and weight. This video provides an overview of the key efficacy and safety data, including metabolic and weight changes, from clinical trials for manic or mixed episodes and depressive episodes associated with BP-1 to help healthcare providers monitor and manage these potential adverse events.

Watch the major depressive disorder video here and the schizophrenia video here.

This resource is intended for educational purposes only and is intended for US healthcare professionals. Healthcare professionals should use independent medical judgment. All decisions regarding patient care must be handled by a healthcare professional and be made based on the unique needs of each patient.

VRLR-US-00016-MC, V1.0
Approved 02/2025
AbbVie Medical Affairs

Andrew Cutler, MD

Clinical associate professor of psychiatry at State University of New York Upstate Medical University in Syracuse, New York, and chief medical officer of the Neuroscience Education Institute in Carlsbad, California

Roger McIntyre, MD, FRCPC

Professor of psychiatry and pharmacology at the University of Toronto and a practicing clinical psychiatrist

A Focus on Metabolic Parameters and Weight Changes With an Atypical Antipsychotic for Bipolar I Disorder

More from the series:

Specialties

Events

Year Round Education

HMP Global Products